Oragenics, Inc. announced that as previously disclosed, the company entered into an Asset Purchase Agreement with Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. (?Odyssey?). On December 28, 2023, the Company successfully closed the Odyssey Purchase Agreement. In connection with the Closing of the Odyssey Purchase Agreement and as contemplated by the Purchase Agreement, effective as of the Closing, the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, who has served as President and CEO of Odyssey since 2018, pursuant to which he will serve as the President of the Company (Employment Agreement).

Under the terms of the Employment Agreement, Mr. Redmond?s employment with the Company became effective December 28, 2023 (the ?Effective Date?) and will continue through the first anniversary of the Effective Date and shall automatically be extended for an additional 12 month term. Ms. Kimberly Murphy, who had served as the President and Chief Executive Officer of the Company prior to the closing of the Odyssey Purchase Agreement, shall continue to serve as the Company?s Chief Executive Officer and as a member of the Company?s Board of Directors. Mr. Redmond has 35 years of commercial experience with medical device companies, having held various sales and marketing leadership positions that helped accelerate growth at companies to multiples of their previous revenue and valuation.

Mr. Redmond also has significant experience in raising capital and securing licensing and distribution deals with major biotech and pharmaceutical companies. In his new position, Mr. Redmond will oversee the growth of Oragenics? neurology product pipeline and intranasal drug delivery technologies.